Skip to main content

Press releases | April 13, 2022

Fried Frank counseled BofA Securities as financial advisor to Halozyme Therapeutics, Inc. (“Halozyme") in its US$960 million acquisition of Antares Pharma, Inc. (“Antares"). Halozyme is a biopharmaceutical company advising key aspects of new drug development. Antares is a specialty pharmaceutical company focused on the development and commercialization of pharmaceutical products and technologies in targeted therapeutic areas. The transaction creates a leading drug delivery business with broadly licensable opportunities and is expected to close in the first half of 2022.

The Fried Frank team was led by corporate partner Roy Tannenbaum and included corporate partner Philip Richter and corporate associate Nate Goldfinger.


This communication is for general information only. It is not intended, nor should it be relied upon, as legal advice. In some jurisdictions, this may be considered attorney advertising. Please refer to the firm’s data policy page for further information.